Nyxoah S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NYXH research report →
About the company
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
- CEO
- Olivier Taelman
- IPO
- 2021
- Employees
- 163
- HQ
- Mont-Saint-Guibert, WBR, BE
Price Chart
- Market Cap
- $68.12M
- P/E
- -0.70
- P/S
- 3.65
- P/B
- 1.80
- EV/EBITDA
- -1.07
- Div Yield
- 0.00%
- Gross Margin
- 48.34%
- Op Margin
- -527.24%
- Net Margin
- -527.77%
- ROE
- -164.44%
- ROIC
- -116.24%
- Revenue
- $10.02M · 121.63%
- Net Income
- $-90,085,000 · -52.08%
- EPS
- $-2.37 · -30.94%
- Op Income
- $-82,942,000
- FCF YoY
- -23.51%
- 52W High
- $8.59
- 52W Low
- $1.26
- 50D MA
- $2.44
- 200D MA
- $4.03
- Beta
- 0.96
- Avg Volume
- 260.53K
Get TickerSpark's AI analysis on NYXH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NYXH coverage
Recent articles, reports, and earnings notes.
No research on NYXH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NYXH report →Similar companies
Peers in the same neighborhood.